GIC

Showing 2085 articles
Business

Aon Posts Strong 2025, Eyes Steady Growth Amid Strategic Push

The global professional services firm reported sustained organic revenue growth and margin expansion for 2025, backed by its '3x3' strategic plan and technology investments. Leadership provided an upbeat outlook for 2026, targeting continued mid-single-digit growth and further profitability gains.

Business

AbCellera Biologics: A Valuation Crossroads After Volatile Returns

Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.

Business

AbCellera Biologics: A Tale of Two Valuations Amid Steep Share Decline

Shares of antibody discovery firm AbCellera Biologics plunged 16.8% last week, reigniting debate over its true worth. While a discounted cash flow model suggests deep undervaluation, its sky-high price-to-sales ratio paints a starkly different picture, leaving investors to navigate conflicting signals in a volatile biotech market.

Business

From Bitcoin to AI: IREN's Strategic Pivot Gains Momentum as Anthropic's $20B Raise Highlights Infrastructure Demand

Fueled by a landmark $20 billion funding round for AI firm Anthropic, infrastructure provider IREN is seeing its strategic shift from cryptocurrency mining to AI data centers validated by investors. With a key Microsoft partnership and surging capital flows into AI, the company's stock performance reflects a broader market reassessment of its role in high-performance computing.